Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).

Published in: Expert review of anti-infective therapy (2022)

Initial pharmacokinetic and safety data suggest that DAAs have high efficacy and a low risk of adverse events during pregnancy. As more pharmacokinetic and epidemiologic data become available, DAAs could become a preferred option for treating HCV during pregnancy and elimination of perinatal transmission of hepatitis C virus.

Keyphrases

hepatitis c virus
human immunodeficiency virus
electronic health record
pregnant women
big data
data analysis
machine learning
artificial intelligence
antiretroviral therapy
deep learning